Please login to the form below

Not currently logged in


This page shows the latest eteplirsen news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Spark’s Luxturna, but rejects Sarepta again

CHMP backs Spark’s Luxturna, but rejects Sarepta again

Sarepta setback. There was bitter news from the CHMP for Sarepta, as the panel turned down its application for Duchenne muscular dystrophy drug Exondys (eteplirsen) for a second time, setting up ... Eteplirsen was approved in the US as Exondys 51 in 2016,

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...